Cannabidiol (CBD) in patients with mild to moderate symptoms of coronavirus 2019: a randomized, double-blind, placebo-controlled clinical trial

The aim of this work is to conduct a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of cannabidiol (CBD - 300 mg a day) in patients infected with SARS-CoV-2. The specific objectives are to assess whether, in patients with mild and moderate forms of SARS-CoV-2, daily use of CBD 300 mg for fourteen days is capable of: i) decrease viral load; ii) modify inflammatory parameters, such as cytokines, measured from serum; iii) reduceclinical and emotional symptoms through daily clinical evaluation; iv) improve the quality of life and sleep; v) reduce hospitalization and worsen the severity of the disease; v) Monitor the possible adverse effects of CBD use in these patients vi) Evaluate whether CBD 300 mg can prevent depression, burnout, PTSD and other neuropsychiatric disorders in SARS-CoV-2 patients; vii) Evaluate if CBD can prevent central structural and functional abnormalities in SARS-CoV-2 patients as assessed by DTI diffusion tensor imaging and rsfMRI - resting-state functional magnetic resonance imaging. (AU)